Our Presence in the UK

Our medicines
Our global portfolio spans major therapeutic categories, including gastrointestinal, neurology, cardiovascular, pain management, oncology and anti-infectives. We are able to make the prices of our drugs accessible because we manage the entire supply chain, from the production of active ingredients to the development of formulations to distribution through an optimized supply chain. We leverage our strength – one of the largest manufacturing bases in India – to offer our customers a distinct cost advantage and a distributed production base in four countries (India, the United States, the United Kingdom, and Mexico).

Our in-depth knowledge of regulations and intellectual property also enables us to make medicines accessible to millions of people worldwide. We want to be the first to launch complex generic drugs and differentiated formulations that can meet the growing clinical needs of a large number of patients. We also work with historical partners to expand our offer by entering into collaborations and licensing agreements. We work with great commitment and determination to speed up access to affordable medicines, offering value to our patients and healthcare partners. Our medicines are available in various formulations such as tablets, capsules and solutions for injection.

For more information on our products, visit:eMC site

View our product list here >> Product list

Our Presence in the UK

Our medicines
Our global portfolio spans major therapeutic categories, including gastrointestinal, neurology, cardiovascular, pain management, oncology and anti-infectives. We are able to make the prices of our drugs accessible because we manage the entire supply chain, from the production of active ingredients to the development of formulations to distribution through an optimized supply chain. We leverage our strength – one of the largest manufacturing bases in India – to offer our customers a distinct cost advantage and a distributed production base in four countries (India, the United States, the United Kingdom, and Mexico).

Our in-depth knowledge of regulations and intellectual property also enables us to make medicines accessible to millions of people worldwide. We want to be the first to launch complex generic drugs and differentiated formulations that can meet the growing clinical needs of a large number of patients. We also work with historical partners to expand our offer by entering into collaborations and licensing agreements. We work with great commitment and determination to speed up access to affordable medicines, offering value to our patients and healthcare partners. Our medicines are available in various formulations such as tablets, capsules and solutions for injection.

For more information on our products, visit:eMC site

View our product list here >> Product list

Our R&D

Our R&D center in Cambridge is part of Dr. Reddy’s R&D network, driven by the urgent need for more affordable, innovative medications because Good Health Can’t Wait.

At the heart of every medicine is the active ingredient. Accelerating access to innovative and affordable medicines begins with making active ingredients more affordable. In Cambridge, we focus on developing technical solutions to produce highly complex APIs. With a history in world-leading asymmetric catalysis together with continuous processing and diligent analytical support, our teams create cleaner, quicker, and more efficient routes to these complex molecules. Furthermore, we work closely with our manufacturing sites to scale up these processes to meet the demand for high-quality APIs.

Our R&D

Our R&D center in Cambridge is part of Dr. Reddy’s R&D network, driven by the urgent need for more affordable, innovative medications because Good Health Can’t Wait.

At the heart of every medicine is the active ingredient. Accelerating access to innovative and affordable medicines begins with making active ingredients more affordable. In Cambridge, we focus on developing technical solutions to produce highly complex APIs. With a history in world-leading asymmetric catalysis together with continuous processing and diligent analytical support, our teams create cleaner, quicker, and more efficient routes to these complex molecules. Furthermore, we work closely with our manufacturing sites to scale up these processes to meet the demand for high-quality APIs.

API Manufacturing

Read all

Cookie preference center